FY2022 – FY2025 · TEM · IPO 2024-06-14 · CIK 1717115
Tempus AI Financials
Tempus AI direct-listed on Nasdaq June 14, 2024. The page covers the post-IPO record — FY2022 to FY2025 revenue, the Diagnostics-vs-Data-and-applications product-line split, Oncology and Hereditary test volumes, Insights Net Revenue Retention, named pharma partners (AstraZeneca, GSK), and the February 2025 Ambry Genetics acquisition that reshaped the diagnostics mix. The trend lines are intentionally short — the public history is short — and the page resists treating one year of data as a long-run pattern.
Tests delivered (FY2025)
~801,000
340,500 Oncology + 460,500 Hereditary, per the FY2025 10-K MD&A.
FY2025 Insights NRR
126%
Net Revenue Retention vs. FY2024 cohort.
Cash & equivalents (2025-12-31)
$604.8M
EDGAR XBRL CashAndCashEquivalentsAtCarryingValue, end-of-period.
Stock price (TEM)
Live current price plus the post-IPO history. The chart's range covers from the June 14, 2024 Nasdaq IPO to today; for context, this is a much shorter window than most charts on this site, by design. Chart updates during US market hours (9:30 a.m. – 4:00 p.m. Eastern, Monday – Friday) via TradingView's embed widget.
Most recent Tempus AI SEC filings
The freshness frontier — the latest filing of each material form type, fetched live from EDGAR. The 10-K marked “Anchors this page” is the source of every value below; the others are surfaced for transparency.
1 material filings have been filed since the anchor 10-K above (1 DEF 14A). The financial metrics on this page (revenue, segment splits, test volumes, headcount) are still anchored to the 10-K because subsequent filings either don't include those metrics or haven't been filed yet.
Annual revenue
As reported on the consolidated statement of operations in each year's 10-K. Sourced live from SEC EDGAR XBRL; the underlying tag is RevenueFromContractWithCustomerExcludingAssessedTax. Tempus AI listed on Nasdaq in June 2024, so FY2022 is the earliest annual revenue available in EDGAR's XBRL series — the chart is intentionally short. The FY2024 → FY2025 jump (+83% YoY) reflects both organic growth in Diagnostics and the February 2025 Ambry acquisition adding a Hereditary testing line.
Show table
| Fiscal year | Revenue | Source |
|---|---|---|
| FY2022 | $320.7M | 10-K filed 2025-02-24 |
| FY2023 | $531.8M | 10-K filed 2026-02-24 |
| FY2024 | $693.4M | 10-K filed 2026-02-24 |
| FY2025 | $1.27B | 10-K filed 2026-02-24 |
Diagnostics vs. Data and applications revenue
Tempus AI operates as a single reportable segment, but the income statement disaggregates revenue into two product lines: Diagnostics (Oncology and, since the February 2025 Ambry acquisition, Hereditary tests) and Data and applications (the Insights de-identified-data licensing business plus Trials, Next, and Algos). The FY2024 10-K labeled these “Genomics” and “Data and services”; the FY2025 10-K renamed them but the dollar amounts for FY2023 and FY2024 are unchanged. The chart starts at FY2023 because that is the earliest year cleanly disclosed in the post-IPO 10-Ks.
Show table
| FY | Diagnostics | Data & apps | Diag. % | Source |
|---|---|---|---|---|
| FY2023 | $363.0M | $168.8M | 68% | 10-K filed 2025-02-24 |
| FY2024 | $451.7M | $241.6M | 65% | 10-K filed 2026-02-24 |
| FY2025 | $955.4M | $316.4M | 75% | 10-K filed 2026-02-24 |
Test volume (Diagnostics)
Number of Oncology and Hereditary tests delivered per fiscal year, as disclosed in each 10-K's MD&A “Comparison of Years Ended” narrative. Hereditary tests entered the portfolio with the February 2025 Ambry Genetics acquisition, which is why the line is zero before FY2025. The 10-Ks also disclose average revenue per Oncology NGS test for some years (~$1,450 in FY2023, ~$1,510 in FY2024); FY2025 average revenue per test is not separately disclosed in the 10-K because the reimbursement mix shifted with the addition of Hereditary.
Show table
| FY | Oncology | Hereditary | Total | Avg rev / Oncology test | Source |
|---|---|---|---|---|---|
| FY2023 | 218,700 | 0 | 218,700 | $1,450 | 10-K filed 2025-02-24 |
| FY2024 | 270,800 | 0 | 270,800 | $1,510 | 10-K filed 2025-02-24 |
| FY2025 | 340,500 | 460,500 | 801,000 | — | 10-K filed 2026-02-24 |
Net Revenue Retention — Insights data-licensing cohort
Tempus discloses Net Revenue Retention (NRR) for the Insights data-licensing customer cohort: it compares Insights revenue from a customer cohort in year N to the same customer cohort's revenue in year N+1. Above 100% means the cohort spent more in the later year than the prior year. NRR is not always disclosed every quarter; the values below are the years that the 10-Ks disclose. The trend — 140% in FY2024 to 126% in FY2025 — signals decelerating expansion within the existing data-licensing customer base, which is one of the more closely-watched signals on the Tempus thesis.
Year-end headcount
As disclosed in the “Human Capital” subsection of each year's 10-K. Tempus discloses a rounded total (e.g., “more than 3,800 employees”) plus a technical-employee subtotal that covers product, engineering, and R&D roles. The FY2024 → FY2025 increase is partly organic and partly the Ambry Genetics acquisition (closed February 2025).
Show table
| FY end | Total (rounded) | Technical | Source |
|---|---|---|---|
| FY2024 | ~2,400 | 776 | 10-K filed 2025-02-24 |
| FY2025 | ~3,800 | 1,232 | 10-K filed 2026-02-24 |
Named pharma partners
Pharmaceutical partners named in the FY2025 10-K. Tempus discloses these by name as “strategic collaborations” whose total potential value is included in the Remaining Total Contract Value disclosure under the Data and applications product line. The 10-K does not disclose individual contract dollar amounts, so the table presents only what's publicly named.
| Partner | Kind | Status | Note | Source |
|---|---|---|---|---|
| AstraZeneca | Strategic collaboration / Master Services Agreement | active multi-year | Disclosed by name throughout the 10-K. Total potential value of the AstraZeneca + GSK strategic collaborations is included in the Remaining TCV disclosure under the Data and applications product line; both could be satisfied by purchase of any Tempus product or service. | 10-K filed 2026-02-24 |
| GlaxoSmithKline (GSK) | Strategic collaboration | active multi-year | Disclosed by name in the FY2025 10-K as one of the two named strategic-collaboration partners alongside AstraZeneca. | 10-K filed 2026-02-24 |
Other metrics
Operating income, net income, stock-based compensation, and operating cash flow — the standard 10-K-derived secondary metrics. All values pulled live from SEC EDGAR XBRL. The big FY2024 net loss reflects IPO-related stock-based compensation tied to RSU performance-vesting that triggered at the June 2024 IPO; FY2025's much smaller loss is the run-rate post that one-time event.
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating Income (Loss) | -$265.4M | -$196.1M | -$691.1M | -$252.9M |
| Net Income (Loss) | -$289.8M | -$214.1M | -$705.8M | -$245.0M |
| Stock-Based Compensation | $0 | $0 | $534.1M | $124.7M |
| Operating Cash Flow | -$168.2M | -$214.3M | -$189.0M | -$218.1M |
Key events
Material corporate events — entity formation, name changes, major acquisitions, and the June 2024 Nasdaq IPO.
- Aug 1, 2015 milestone Founded as Bioin, LLC by Eric Lefkofsky
- Jan 1, 2016 milestone Renamed Tempus Labs, Inc.
- Jan 1, 2022 acquisition Acquired Highline Consulting (renamed Tempus Compass) — clinical-trials CRO
- Dec 5, 2023 milestone Renamed Tempus AI, Inc.
- Jun 14, 2024 milestone IPO on Nasdaq under ticker TEM
- Feb 1, 2025 acquisition Acquired Ambry Genetics — adds Hereditary testing line; closed in February 2025
- Aug 7, 2025 milestone Reincorporated from Delaware to Nevada
Methodology & data sources
Live data. Annual revenue, R&D, operating income, net income, stock-based compensation, and operating cash flow are sourced live from Tempus AI's SEC EDGAR XBRL company-facts endpoint. If EDGAR is unreachable when the page is being prepared, the page is not updated, so visitors never see stale fallback numbers.
Hand-curated, source-tagged. The Diagnostics-vs-Data-and-applications product-line split (renamed from “Genomics” / “Data and services” in the FY2025 10-K), per-FY Oncology and Hereditary test volumes, Net Revenue Retention for the Insights data-licensing cohort, year-end headcount, named pharma partners (AstraZeneca and GSK), and the key-events timeline (founding, name changes, IPO, Ambry acquisition, Nevada reincorporation) are not exposed in EDGAR companyfacts JSON. Each value is hand-curated from the underlying 10-K filing's narrative section, and tagged with the filing's accession number. When a newer 10-K is filed than the one a value was last verified against, a “Verification due” banner appears next to the affected section.
Refresh cadence. Hand-curated values are re-verified quarterly, aligned with Tempus's 10-Q filing cadence. Named pharma partners are checked against each 10-K and 10-Q's MD&A and the company's investor-relations press releases on every refresh.
What's intentionally not here. Medical or clinical claims about test efficacy or accuracy — this page is financials only. Competitor comparisons against Guardant Health, Foundation Medicine, Natera, or 23andMe — those are different business shapes and not on the AI pure-play roster. Speculation about future pharma partnerships not yet disclosed. AI-hype framing — Tempus is a healthcare-and-AI hybrid with three distinct revenue streams, not “an AI company” in the LLM sense. Live market cap (different licensing for market-data fields beyond price; the page refreshes quarterly, so a real-time market-cap calc against fresh share counts would be misleading).
Cross-references. Tempus AI on the AI Pure-Plays roster. Tech Filings for every Tempus AI SEC filing in chronological order. Tech Acquisitions for the Ambry deal (and any future Tempus M&A).
Last updated: 2026-04-30 17:41 UTC. Latest 10-K on EDGAR: 0001193125-26-066961 filed 2026-02-24. Hand-curated source-tag anchor: 0001193125-26-066961.